Exercise Training and Inflammatory Mediators in COPD

COPD Clinical Trial

Official title:

Effect of Exercise Training on Inflammatory Mediators in COPD

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03853174
• Other study ID #: COPD and exercise
• Status: Completed
• Phase: N/A
• Start date: January 1, 2019
• Est. completion date: April 27, 2019

Study information

• Verified date: December 2019
• Source: Faculty of Medicine, Sousse
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Chronic obstructive pulmonary disease (COPD) is widely spread all over the world. It is predicted to be the third leading cause of death by 2020[1]. COPD is a common, preventable treatable disease that is characterized by an airflow limitation which is not fully reversable[2].

Description:

Chronic obstructive pulmonary disease (COPD) is widely spread all over the world. It is predicted to be the third leading cause of death by 2020. COPD is a common, preventable treatable disease that is characterized by an airflow limitation which is not fully reversable.Not only the long-term exposition to noxious particles and gases contributes to the development of COPD, but also so many others factors such as genetics and cigarette smoking. It has been shown that cigarettes are harmful and contributed to different extra pulmonary disorders. Indeed, it induced a systemic inflammation that was considered as a key process in the pathogenesis of COPD and triggered the activation of inflammatory cells and an abnormal increase of circulating cytokines such as CRP, interleukin (IL6), IL8, tumor necrosis factor alpha (TNF alpha) and leptin.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 28
• Est. completion date: April 27, 2019
• Est. primary completion date: April 17, 2019
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 40 Years to 75 Years

Eligibility

Inclusion Criteria:

• COPD diagnosed by pulmonary function testing

• Clinically stable

• Abscence of other obstructive diseases

• Signed written consent

Exclusion Criteria:

• Neuromuscular diseases -Severe psychiatric, neurologic or musculoskeletal conditions and /or instable--- --

• cardiovascular diseases.

• Contre-indications to physical therapy

• Acute exacerbations a month before the intervention

Related Conditions & MeSH terms

• COPD

Intervention

Other:
• Endurance Training ET
Endurance training were prformed. Intensity was gradually increased.
• Resistance Training RT
Resistance training were prformed. Intensity was gradually increased.

Locations

Country	Name	City	State
Tunisia	Amal Acheche	Sousse

Sponsors (1)

Lead Sponsor	Collaborator
Faculty of Medicine, Sousse

Country where clinical trial is conducted

Tunisia, 

References & Publications (4)

authors non mentionned., global initiative for chronic lung disease. 2017

Barnes PJ. Cellular and molecular mechanisms of chronic obstructive pulmonary disease. Clin Chest Med. 2014 Mar;35(1):71-86. doi: 10.1016/j.ccm.2013.10.004. Epub 2013 Dec 12. Review. — View Citation

Barnes PJ. Inflammatory mechanisms in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2016 Jul;138(1):16-27. doi: 10.1016/j.jaci.2016.05.011. Epub 2016 May 27. Review. — View Citation

Molfino NA, Jeffery PK. Chronic obstructive pulmonary disease: histopathology, inflammation and potential therapies. Pulm Pharmacol Ther. 2007;20(5):462-72. Epub 2006 May 6. Review. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Enzyme linked immunosorbent assay for serum cytokines levels change	The interleukines were determined by ELISA assays with commercial kits	Baseline, 6 months